Artiva Biotherapeutics, Inc.

**Signal Note: RA Capital initiates $42.3M position in ARTV** RA Capital's entry into Artiva signals confidence in the company's engineered T cell platform, particularly ARTV-501 for relapsed/refractory multiple myeloma, which is advancing toward clinical data readouts. The $42.3M stake (9.9M shares) represents a meaningful conviction bet from a top-tier crossover investor and suggests near-term catalysts—likely Phase 1b/2 efficacy and safety data—justify the entry point.